SIGY logo

Sigyn TherapeuticsOTCPK:SIGY Stock Report

Market Cap US$4.5m
Share Price
US$2.80
My Fair Value
1Yn/a
7D0%
Portfolio Value
​
View

Sigyn Therapeutics, Inc.

OTCPK:SIGY Stock Report

Market Cap: US$4.5m

Sigyn Therapeutics (SIGY) Stock Overview

A development-stage company, develops and sells medical devices to treat cancer and infectious disease disorders in the United States. More details

SIGY fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Risk Analysis

Negative shareholders equity

Earnings have declined by 20.3% per year over past 5 years

Makes less than USD$1m in revenue ($0)

Has less than 1 year of cash runway

+ 3 more risks

SIGY Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Sigyn Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sigyn Therapeutics
Historical stock prices
Current Share PriceUS$2.80
52 Week HighUS$5.75
52 Week LowUS$2.49
Beta-0.87
1 Month Change1.82%
3 Month Changen/a
1 Year Changen/a
3 Year Change-52.54%
5 Year Changen/a
Change since IPO-96.45%

Recent News & Updates

Recent updates

Shareholder Returns

SIGYUS Medical EquipmentUS Market
7D0%-0.2%1.3%
1Yn/a5.8%14.6%

Return vs Industry: Insufficient data to determine how SIGY performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how SIGY performed against the US Market.

Price Volatility

Is SIGY's price volatile compared to industry and market?
SIGY volatility
SIGY Average Weekly Movementn/a
Medical Equipment Industry Average Movement8.1%
Market Average Movement6.3%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market3.1%

Stable Share Price: SIGY's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine SIGY's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20194Jim Joycewww.sigyntherapeutics.com

Sigyn Therapeutics, Inc., a development-stage company, develops and sells medical devices to treat cancer and infectious disease disorders in the United States. Its lead product candidate is Sigyn therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community-acquired pneumonia, drug-resistant bacterial infections, and emerging pandemic threats. The company is also involved in the evaluation of Sigyn therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.

Sigyn Therapeutics, Inc. Fundamentals Summary

How do Sigyn Therapeutics's earnings and revenue compare to its market cap?
SIGY fundamental statistics
Market capUS$4.50m
Earnings (TTM)-US$3.25m
Revenue (TTM)n/a
0.0x
P/S Ratio
-1.4x
P/E Ratio

Is SIGY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SIGY income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$3.25m
Earnings-US$3.25m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-2.02
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-48.6%

How did SIGY perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/23 20:13
End of Day Share Price 2025/07/11 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sigyn Therapeutics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Siddharth RajeevFundamental Research Corp.